MAPK3 (Mitogen-Activated Protein Kinase 3), commonly known as ERK1 (Extracellular Signal-Regulated Kinase 1) or p44 MAPK, is a serine/threonine kinase that plays critical roles in cellular signal transduction, neuronal function, and synaptic plasticity. As a key component of the MAPK/ERK signaling pathway, ERK1 transduces extracellular signals from growth factors, neurotransmitters, and cellular stress into intracellular responses that regulate gene expression, cell survival, and neuronal plasticity.
ERK1 has emerged as a significant player in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. Dysregulation of ERK1 signaling contributes to amyloid-beta (Aβ) toxicity, tau hyperphosphorylation, dopaminergic neuron degeneration, and neuroinflammation. The pathway represents both a therapeutic target and a potential biomarker for neurodegeneration[@kim2022][@maqbool2023].
| Extracellular Signal-Regulated Kinase 1 (ERK1/MAPK3) |
|---|
| Gene Symbol | MAPK3 |
| Protein Name | ERK1, p44 MAPK |
| Chromosome | 16p11.2 |
| NCBI Gene ID | [5595](https://www.ncbi.nlm.nih.gov/gene/5595) |
| OMIM | 601795 |
| Ensembl ID | ENSG00000102882 |
| UniProt ID | [P27361](https://www.uniprot.org/uniprot/P27361) |
| Protein Family | MAPK family, ERK subfamily |
| Subcellular Location | Cytoplasm, nucleus |
| Associated Diseases | AD, PD, ALS, Stroke, Brain Injury |
¶ Gene and Protein Structure
The MAPK3 gene is located on chromosome 16p11.2 and spans approximately 9.4 kb of genomic DNA. The gene consists of 10 exons that encode a protein of 367 amino acids with a molecular weight of approximately 44 kDa. The gene promoter contains binding sites for multiple transcription factors including Sp1, AP-1, and CREB, allowing for complex regulation in response to various cellular signals[@roskoski2024].
¶ Protein Domain Architecture
ERK1 contains several functional domains:
- N-terminal kinase domain (residues 1-150): Contains the activation loop and substrate binding site
- C-terminal regulatory domain (residues 150-367): Contains docking motifs for substrates and regulators
- TEY motif (Thr202/Tyr204): Dual phosphorylation site required for activation
The kinase domain adopts a typical bilobal structure with:
- N-lobe: ATP-binding pocket with glycine-rich loop
- C-lobe: Catalytic site and substrate recognition surface
The MAPK/ERK cascade is activated by diverse extracellular stimuli:
flowchart TD
A["Growth Factors<br/>BDNF, NGF, EGF] --> B["RTK Activation]
A --> C["G-Protein Coupled Receptors]
A --> D["Ionotropic Receptors<br/>Glutamate NMDA/AMPA]
B --> E[""Ras GEFs]
C --> E
D --> E
E --> F["Ras-GTP]
F --> G["Raf kinases<br/>ARAF, BRAF, RAF1]
G --> H["MEK1/2"]
H --> I["ERK1/2]
I --> J["Nuclear Targets<br/>Transcription Factors]
I --> K["Cytoplasmic Targets<br/>Synaptic Proteins]
style I fill:#e1f5fe,stroke:#333
style J fill:#c8e6c9,stroke:#333
style K fill:#c8e6c9,stroke:#333
| Level |
Kinase |
Function |
| MAPKKK |
RAF (A/B/C) |
Activates MEK |
| MAPKK |
MEK1/2 |
Phosphorylates ERK |
| MAPK |
ERK1/2 |
Effector kinases |
| MAPKAPK |
RSK, MSK, MNK |
Secondary effectors |
ERK1 activity is tightly regulated through:
- Phosphorylation: Dual phosphorylation at Thr202 and Tyr204 by MEK1/2 is required for full activation
- Dephosphorylation: MKP family phosphatases (DUSP1, DUSP6) inactivate ERK
- Subcellular localization: Nuclear import/export controls signaling duration
- Scaffold proteins: KSR, JIP, MP1 coordinate pathway assembly
ERK1 plays a critical role in synaptic plasticity, the cellular basis of learning and memory[@huang2020]:
- Long-term potentiation (LTP): ERK1 is activated during LTP and is required for LTP maintenance
- Long-term depression (LTD): ERK1 signaling contributes to AMPA receptor internalization
- Dendritic spine morphogenesis: ERK1 regulates actin cytoskeleton dynamics
- Local protein synthesis: ERK1 phosphorylates translational regulators (eCREB, eIF4E)
During brain development, ERK1 signaling controls:
- Neurogenesis: Regulates progenitor cell proliferation and differentiation
- Migration: Controls neuronal migration via cytoskeletal remodeling
- Axonal guidance: Mediates growth cone responses to guidance cues
- Synaptogenesis: Orchestrates presynaptic and postsynaptic differentiation
ERK1 translocates to the nucleus where it phosphorylates:
- Transcription factors: CREB, Elk-1, c-Fos, c-Myc
- Chromatin regulators: Histone H3, HDAC
- RNA processing: Alternative splicing factors
¶ Brain Expression and Localization
ERK1 is widely expressed throughout the brain with highest levels in regions associated with cognitive function[@kim2022]:
| Brain Region |
Expression Level |
Functional Significance |
| Hippocampus |
Very High |
CA1-CA3, dentate gyrus — memory processing |
| Cerebral Cortex |
High |
Layer 2/3, 5 pyramidal neurons — cognition |
| Basal Forebrain |
High |
Cholinergic neurons — attention |
| Amygdala |
Moderate-High |
Emotional memory |
| Cerebellum |
Moderate |
Purkinje cells — motor learning |
| Striatum |
Moderate |
Medium spiny neurons — movement |
- Excitatory glutamatergic neurons: High expression — synaptic plasticity
- Inhibitory GABAergic neurons: Moderate expression — network regulation
- Astrocytes: Low-Moderate — glia-neuron signaling
- Microglia: Inducible — activation-dependent
- Oligodendrocytes: Moderate — myelination regulation
ERK1 exhibits dynamic subcellular distribution:
- Dendritic shafts: Associates with dendritic spines
- Synaptic vesicles: Regulates presynaptic function
- Nucleus: Controls gene expression programs
- Mitochondria: Influences metabolic function
ERK1 is deeply involved in Aβ-induced neuronal dysfunction[@maqbool2023][@choi2019]:
- Aβ-induced activation: Oligomeric Aβ triggers ERK1 phosphorylation
- Synaptic toxicity: ERK1 activation contributes to synaptic loss
- Tau hyperphosphorylation: ERK1 phosphorylates tau at multiple sites
- Gene expression dysregulation: Alters transcription of synaptic proteins
ERK1 phosphorylates tau at disease-relevant sites:
- Ser262 (multiple repeat isoforms)
- Ser396 (PHF-tau epitope)
- Ser404 (AD-tau epitope)
The interaction between Aβ, ERK1, and tau forms a pathogenic feed-forward loop:
flowchart TD
A["Amyloid-beta<br/>Oligomers] --> B["ERK1 Activation]
B --> C["Tau<br/>Hyperphosphorylation]
C --> D["NFT Formation]
D --> E["Synaptic<br/>Dysfunction]
E --> F["Neuronal Death]
A --> F
B --> E
style C fill:#ffcdd2,stroke:#333
style D fill:#ffcdd2,stroke:#333
ERK1 mediates neuroinflammatory responses in AD[@xu2021]:
- Microglial activation: Aβ stimulates ERK1 in microglia
- Cytokine production: ERK1 regulates IL-1β, TNF-α, IL-6
- Neuronal stress: Inflammatory ERK1 signaling exacerbates toxicity
Targeting ERK1 in AD:
| Strategy |
Approach |
Status |
| MEK inhibitors |
Block ERK activation |
Preclinical |
| Tau kinase inhibitors |
Prevent tau phosphorylation |
Research |
| Anti-inflammatory |
Reduce ERK-mediated inflammation |
Clinical trials |
| Neurotrophic factors |
Activate protective ERK signaling |
Research |
ERK1 plays complex roles in PD pathogenesis[@wang2023][@cunningham2020]:
- Neuroprotective signaling: Activity-dependent ERK1 activation promotes survival
- Oxidative stress response: ERK1 mediates antioxidant gene expression
- Mitochondrial function: ERK1 regulates mitochondrial dynamics
- Alpha-synuclein toxicity: Modulates synuclein phosphorylation
The LRRK2 kinase, frequently mutated in familial PD, intersects with ERK1 signaling:
- LRRK2 can phosphorylate MAPK pathway components
- ERK1 activation may compensate for LRRK2 dysfunction
- Combined targeting shows promise in models
ERK1-based therapeutic strategies in PD[@zhang2022]:
- Neuroprotective activation: Activity-based ERK1 stimulation
- Inhibition of pathogenic ERK1: Reducing toxic overactivation
- Combination approaches: ERK1 + LRRK2 or autophagy
In ALS, ERK1 dysregulation contributes to:
- Motor neuron vulnerability
- Glial activation
- Excitotoxicity
- Mitochondrial dysfunction
¶ Stroke and Brain Injury
Following cerebral ischemia, ERK1 has dual roles:
- Early neuroprotective: Promotes survival signaling
- Delayed pathogenic: Contributes to excitotoxicity and inflammation
ERK1 signaling is altered in HD:
- Mutant huntingtin affects ERK1 localization
- Dysregulated ERK1 contributes to transcriptional deficits
Direct Partners:
- MEK1/2: Upstream activator
- DUSP6: Negative regulator
- RSK1/2/3: Downstream effectors
- MNK1/2: Alternative substrate
Substrates:
- Tau protein: Phosphorylation at disease sites
- CREB: Transcriptional activation
- Synapsin: Synaptic vesicle regulation
- PSD-95: Synaptic scaffold modification
ERK1 integrates with multiple pathways:
- PI3K/Akt: Cross-talk in survival signaling
- cAMP/PKA: Synaptic plasticity coordination
- JNK/p38: Stress response balance
- mTOR: Translational control
| Compound |
Target |
IC50 |
Status |
| Trametinib |
MEK1/2 |
0.7 nM |
Approved (cancer) |
| Selumetinib |
MEK1/2 |
0.5-2.3 μM |
Approved (cancer) |
| U0126 |
MEK1/2 |
0.7 μM |
Research |
| FR180204 |
ERK1/2 |
0.5 μM |
Research |
- Biphasic signaling: ERK1 has both protective and pathogenic roles
- Timing dependency: Early vs. late intervention has different effects
- Blood-brain barrier: Drug delivery challenges
- Cell-type specificity: Targeting specific neuronal populations
- Brain-penetrant MEK inhibitors: Designed for CNS indication
- Cell-type specific activation: AAV-mediated approaches
- Combination therapy: ERK1 + disease-modifying agents
| Model |
Modification |
Phenotype |
| MAPK3 knockout |
Deletion |
Viable, mild cognitive deficits |
| MAPK3 conditional KO |
Neuron-specific |
Learning impairment |
| ERK1/2 double KO |
Embryonic lethal |
- |
| ERK1 knockin |
Phospho-mutant |
Altered plasticity |
- APP/PS1 + ERK1: Accelerated amyloid pathology
- MPTP + ERK1: Modulates dopaminergic toxicity
- Tau + ERK1: Enhanced tauopathy
- α-synuclein + ERK1: Altered aggregation
- Phospho-ERK1/2: Detectable in CSF and blood
- Expression changes: Correlate with disease stage
- Therapeutic monitoring: Tracks treatment response
- Develop sensitive detection methods
- Validate in large patient cohorts
- Establish disease-specific signatures
ERK1 connects to multiple NeuroWiki pages:
- Roskoski R. ERK1/2 kinases: From biochemistry to therapy (2024)
- Kim S, Choi K. The role of ERK signaling in neurodegeneration (2022)
- Maqbool M, et al. ERK1/2 activation in Alzheimer's disease (2023)
- Wang J, et al. ERK signaling in Parkinson's disease (2023)
- Huang J, et al. ERK and memory consolidation (2020)
- Meijer A, et al. ERK5/MEK5 signaling in brain development (2020)
- Sun J, et al. ERK pathway in tauopathy (2019)
- Xing L, et al. ERK1/2 and tau pathology in Alzheimer disease (2018)
- Cunningham KL, et al. Role of ERK in dopaminergic neuron survival (2020)
- Raab M, et al. ERK5 in neuronal function and disease (2022)
- Subramaniam S, et al. MEK inhibitors in neurodegenerative disease (2021)
- Li Y, et al. BDNF-ERK signaling in synaptic plasticity (2023)
- Zhang Q, et al. ERK phosphorylation and Parkinson disease (2022)
- Choi DH, et al. Role of MAPK in amyloid-beta toxicity (2019)
- Xu X, et al. ERK1/2 in neuroinflammation (2021)
- Peacock A, et al. ERK and mitochondrial dysfunction in neurodegeneration (2020)